Laekna (HKG:2105) said the phase I clinical trial of LAE102 is progressing effectively, with all 64 subjects in eight groups receiving intravenous and subcutaneous injections of the single ascending dose study, according to a Wednesday filing with the Hong Kong bourse.
LAE102 is a monoclonal antibody selectively targeting ActRIIA, a receptor essential in muscle regeneration and lipid metabolism, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments